Cargando…

Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil

BACKGROUND: The anti-HCV antibody response has not been well characterized during the early phase of HCV infection and little is known about its relationship to the clinical course during this period. METHODS: We analyzed serial anti-HCV antibodies longitudinally obtained from a prospective cohort o...

Descripción completa

Detalles Bibliográficos
Autores principales: Strasak, Alexander M, Kim, Arthur Y, Lauer, Georg M, de Sousa, Paulo S, Ginuino, Cleber F, Fernandes, Carlos A, Velloso, Carlos E, de Almeida, Adilson J, de Oliveira, Jaqueline M, Yoshida, Clara F, zur Wiesch, Julian Schulze, Paranhos-Baccalá, Gláucia, Lang, Stefan, Brant, Larry J, Ulmer, Hanno, Strohmaier, Susanne, Kaltenbach, Lalit, Lampe, Elisabeth, Lewis-Ximenez, Lia L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032695/
https://www.ncbi.nlm.nih.gov/pubmed/21226945
http://dx.doi.org/10.1186/1471-2334-11-15
_version_ 1782197484828753920
author Strasak, Alexander M
Kim, Arthur Y
Lauer, Georg M
de Sousa, Paulo S
Ginuino, Cleber F
Fernandes, Carlos A
Velloso, Carlos E
de Almeida, Adilson J
de Oliveira, Jaqueline M
Yoshida, Clara F
zur Wiesch, Julian Schulze
Paranhos-Baccalá, Gláucia
Lang, Stefan
Brant, Larry J
Ulmer, Hanno
Strohmaier, Susanne
Kaltenbach, Lalit
Lampe, Elisabeth
Lewis-Ximenez, Lia L
author_facet Strasak, Alexander M
Kim, Arthur Y
Lauer, Georg M
de Sousa, Paulo S
Ginuino, Cleber F
Fernandes, Carlos A
Velloso, Carlos E
de Almeida, Adilson J
de Oliveira, Jaqueline M
Yoshida, Clara F
zur Wiesch, Julian Schulze
Paranhos-Baccalá, Gláucia
Lang, Stefan
Brant, Larry J
Ulmer, Hanno
Strohmaier, Susanne
Kaltenbach, Lalit
Lampe, Elisabeth
Lewis-Ximenez, Lia L
author_sort Strasak, Alexander M
collection PubMed
description BACKGROUND: The anti-HCV antibody response has not been well characterized during the early phase of HCV infection and little is known about its relationship to the clinical course during this period. METHODS: We analyzed serial anti-HCV antibodies longitudinally obtained from a prospective cohort of 65 patients with acute HCV infection by using a microparticle enzyme immunoassay AxSYM HCV 3.0 (Abbott Diagnostics) during the first 12 months from HCV acquisition in Rio de Janeiro, Brazil. Spontaneous viral clearance (SVC) was defined as undetectable HCV RNA in serum, in the absence of treatment, for three consecutive HCV PCR tests within 12-months of follow-up. RESULTS: Baseline antibody values were similar among patient groups with self-limiting HCV evolution (n = 34) and persistent viremia (n = 31) [median (interquartile range) signal/cut-off ratio (s/co) 78.7 (60.7-93.8) vs. 93.9 (67.8-111.9), p = 0.26]. During 12-months follow-up, patients with acute spontaneous resolving HCV infection showed significantly lower serial antibody response in comparison to individuals progressing to chronic infection [median (interquartile range) s/co 62.7 (35.2-85.0) vs. 98.4 (70.4-127.4), p < 0.0001]. In addition, patients with self-limiting HCV evolution exhibited an expeditious, sharp decline of serial antibody values after SVC in comparison to those measured before SVC [median (interquartile range) s/co 56.0 (25.4-79.3) vs. 79.4 (66.3-103.0), p < 0.0001]. CONCLUSION: Our findings indicate a rapid short-term decline of antibody values in patients with acute spontaneous resolving HCV infection.
format Text
id pubmed-3032695
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30326952011-02-03 Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil Strasak, Alexander M Kim, Arthur Y Lauer, Georg M de Sousa, Paulo S Ginuino, Cleber F Fernandes, Carlos A Velloso, Carlos E de Almeida, Adilson J de Oliveira, Jaqueline M Yoshida, Clara F zur Wiesch, Julian Schulze Paranhos-Baccalá, Gláucia Lang, Stefan Brant, Larry J Ulmer, Hanno Strohmaier, Susanne Kaltenbach, Lalit Lampe, Elisabeth Lewis-Ximenez, Lia L BMC Infect Dis Research Article BACKGROUND: The anti-HCV antibody response has not been well characterized during the early phase of HCV infection and little is known about its relationship to the clinical course during this period. METHODS: We analyzed serial anti-HCV antibodies longitudinally obtained from a prospective cohort of 65 patients with acute HCV infection by using a microparticle enzyme immunoassay AxSYM HCV 3.0 (Abbott Diagnostics) during the first 12 months from HCV acquisition in Rio de Janeiro, Brazil. Spontaneous viral clearance (SVC) was defined as undetectable HCV RNA in serum, in the absence of treatment, for three consecutive HCV PCR tests within 12-months of follow-up. RESULTS: Baseline antibody values were similar among patient groups with self-limiting HCV evolution (n = 34) and persistent viremia (n = 31) [median (interquartile range) signal/cut-off ratio (s/co) 78.7 (60.7-93.8) vs. 93.9 (67.8-111.9), p = 0.26]. During 12-months follow-up, patients with acute spontaneous resolving HCV infection showed significantly lower serial antibody response in comparison to individuals progressing to chronic infection [median (interquartile range) s/co 62.7 (35.2-85.0) vs. 98.4 (70.4-127.4), p < 0.0001]. In addition, patients with self-limiting HCV evolution exhibited an expeditious, sharp decline of serial antibody values after SVC in comparison to those measured before SVC [median (interquartile range) s/co 56.0 (25.4-79.3) vs. 79.4 (66.3-103.0), p < 0.0001]. CONCLUSION: Our findings indicate a rapid short-term decline of antibody values in patients with acute spontaneous resolving HCV infection. BioMed Central 2011-01-12 /pmc/articles/PMC3032695/ /pubmed/21226945 http://dx.doi.org/10.1186/1471-2334-11-15 Text en Copyright ©2011 Strasak et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Strasak, Alexander M
Kim, Arthur Y
Lauer, Georg M
de Sousa, Paulo S
Ginuino, Cleber F
Fernandes, Carlos A
Velloso, Carlos E
de Almeida, Adilson J
de Oliveira, Jaqueline M
Yoshida, Clara F
zur Wiesch, Julian Schulze
Paranhos-Baccalá, Gláucia
Lang, Stefan
Brant, Larry J
Ulmer, Hanno
Strohmaier, Susanne
Kaltenbach, Lalit
Lampe, Elisabeth
Lewis-Ximenez, Lia L
Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil
title Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil
title_full Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil
title_fullStr Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil
title_full_unstemmed Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil
title_short Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil
title_sort antibody dynamics and spontaneous viral clearance in patients with acute hepatitis c infection in rio de janeiro, brazil
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032695/
https://www.ncbi.nlm.nih.gov/pubmed/21226945
http://dx.doi.org/10.1186/1471-2334-11-15
work_keys_str_mv AT strasakalexanderm antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT kimarthury antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT lauergeorgm antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT desousapaulos antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT ginuinocleberf antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT fernandescarlosa antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT vellosocarlose antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT dealmeidaadilsonj antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT deoliveirajaquelinem antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT yoshidaclaraf antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT zurwieschjulianschulze antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT paranhosbaccalaglaucia antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT langstefan antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT brantlarryj antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT ulmerhanno antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT strohmaiersusanne antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT kaltenbachlalit antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT lampeelisabeth antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil
AT lewisximenezlial antibodydynamicsandspontaneousviralclearanceinpatientswithacutehepatitiscinfectioninriodejaneirobrazil